1. Introduction {#sec1-genes-10-00806}
===============

Gonadotropin releasing hormone (GnRH) is a main regulator of the reproductive endocrine system. Its secretion determines the pattern of secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH activates the release of testosterone in Leydig cells in the testicle. Testosterone is responsible for the male phenotype, body growth, and sperm production \[[@B1-genes-10-00806]\]. Coordinated and pulsatile GnRH secretion is induced due to the synergistic action of neurokinin B, kisspeptin, and dynorphin \[[@B2-genes-10-00806]\]. Neurokinin B stimulates kisspeptin neurons, which leads to GnRH secretion \[[@B3-genes-10-00806]\]. Dysfunctional GnRH release leads to low blood testosterone and pituitary hormone levels, resulting in hypogonadotropic hypogonadism (HH) \[[@B4-genes-10-00806]\]. Impaired testicular function may occur due to a primary testicular disorder or secondary to hypothalamic--pituitary dysfunction (hypogonadotropic). HH may be inherited or caused by non-genetic factors, such as drugs, encephalic trauma, or infiltrative or inflammatory pituitary lesions. Congenital hypogonadotropic hypogonadism (cHH) is a rare genetic disorder characterized by a delayed or absent pubertal development, micropenis, cryptorchidism, androgen/estrogen deficiency, and infertility due to an inadequate secretion of gonadotrophin-releasing hormone (GnRH), with an otherwise structurally and functionally normal hypothalamus and pituitary gland. Low testosterone and pituitary hormone levels confirm the diagnosis \[[@B4-genes-10-00806]\]. Variants in 40 genes have been shown to cause different inherited forms of HH in humans ([Table 1](#genes-10-00806-t001){ref-type="table"}).

This study was initiated after an owner reported a male cat with missing puberty characteristics, such as normal testicle growth and change in primary dentition. The goal of this study was to identify a possible underlying causative genetic defect.

2. Materials and Methods {#sec2-genes-10-00806}
========================

2.1. Ethics Statement {#sec2dot1-genes-10-00806}
---------------------

All animal experiments were performed according to local regulations. The cat in this study is privately owned and was examined with the consent of the owner. The "Cantonal Committee for Animal Experiments" approved the collection of blood samples (Canton of Bern; permit 75/16).

2.2. Animal Selection {#sec2dot2-genes-10-00806}
---------------------

A 3-year-old male domestic shorthair cat with testicular hypoplasia and a persistent primary dentition was investigated. An EDTA blood sample was collected for genomic DNA isolation. Additionally, we used 171 blood samples from cats of various breeds which had been donated to the Vetsuisse Biobank ([Table S1](#app1-genes-10-00806){ref-type="app"}). These samples represented population controls without reports of testicular hypoplasia or a persistent primary dentition.

2.3. Hormone Measurement {#sec2dot3-genes-10-00806}
------------------------

The testosterone level of the affected cat was measured from an EDTA blood sample by labor-zentral.ch (Geuensee, Switzerland).

2.4. DNA Extraction {#sec2dot4-genes-10-00806}
-------------------

Genomic DNA was isolated from EDTA blood with the Maxwell RSC Whole Blood Kit using a Maxwell RSC instrument (Promega). Additionally we used DNA from EDTA blood of 171 non-affected control cats of various breeds that had been stored in our biobank.

2.5. Whole Genome Sequencing {#sec2dot5-genes-10-00806}
----------------------------

An Illumina TruSeq PCR-free DNA library with 350 bp insert size of the affected cat (K532) was prepared. We collected 168 million 2 × 150 bp paired-end reads on a NovaSeq 6000 instrument (18x coverage). Mapping and alignment were performed as described \[[@B35-genes-10-00806]\]. The sequence data were deposited under the study accession PRJEB7401 and the sample accession SAMEA5885924 at the European Nucleotide Archive.

2.6. Variant Calling {#sec2dot6-genes-10-00806}
--------------------

Variant calling and filtering was performed as described \[[@B35-genes-10-00806]\]. To predict the functional effects of the called variants, SnpEFF \[[@B36-genes-10-00806]\] software, together with NCBI annotation release 104 for the Felis_catus_9.0 assembly, was used. For variant filtering we used 38 control genomes, which were produced during other projects of our group ([Table S2](#app1-genes-10-00806){ref-type="app"}).

2.7. Gene Analysis {#sec2dot7-genes-10-00806}
------------------

We used the Felis_catus_9.0 cat reference genome assembly for all analyses. Numbering within the feline *TAC3* gene corresponded to the NCBI RefSeq accessions XM_003988924.5 (mRNA) and XP_003988973.1 (protein).

2.8. Sanger Sequencing {#sec2dot8-genes-10-00806}
----------------------

The *TAC3*:c.220G\>A variant was genotyped by direct Sanger sequencing of PCR amplicons. A 400 bp PCR product was amplified from genomic DNA using AmpliTaqGold360Mastermix together with primers 5'-AGC CCA CTT CTC TTC CAG TG -3' (Primer F) and 5'-AGA GGG GAT TCA GGT CAC AA-3' (Primer R). After treatment with exonuclease I and alkaline phosphatase, amplicons were sequenced on an ABI 3730 DNA Analyzer. Sanger sequences were analyzed using Sequencher 5.1 software.

3. Results {#sec3-genes-10-00806}
==========

3.1. Clinical Examination {#sec3dot1-genes-10-00806}
-------------------------

A 3-year-old male domestic shorthair cat was presented with persistent primary dentition consisting of one primary maxillary canine ([Figure 1](#genes-10-00806-f001){ref-type="fig"}). Upon examination there was one small right testicle located in the scrotum. The left testicle could not be located. It was neither scrotal, nor palpable in the inguinal area. The external genitalia, including the urethral orifice, were in the normal position, although with a juvenile appearance because of their small size. The hair coat had an unkempt appearance. The cat had small body size but proportional growth. It had reportedly displayed mounting behavior toward another female cat in the household and showed an increasingly dominant--aggressive behavior toward other cats outside. The cat was presented for a follow-up examination at 4 years of age. No changes in behavior or the stage of adolescence were noticed.

3.2. Laboratory Findings {#sec3dot2-genes-10-00806}
------------------------

The blood testosterone level of the cat at the age of 4 years was 0.28 ng/mL, which was below the reference range for cats (0.92 ng/mL--9.17 ng/mL).

3.3. Genetic Analysis {#sec3dot3-genes-10-00806}
---------------------

We sequenced the genome of the affected cat and searched for homozygous and heterozygous variants in known candidate genes that were not present in 38 control cats of different breeds ([Table 2](#genes-10-00806-t002){ref-type="table"}).

This analysis identified a single homozygous private protein-changing variant in *TAC3*, a known HH candidate gene \[[@B32-genes-10-00806]\]. The variant was designated as ChrB4:85,517,451C\>T (Felis_catus_9.0 assembly). It is a missense variant, XM_003988924.5:c.220G\>A, predicted to result in the amino acid change XP_003988973.1:p.(Val74Met). This amino acid residue is moderately conserved across mammals. Primates, including humans, have a threonine at this position, while all other investigated mammalian TAC3 sequences have a valine ([Figure 2](#genes-10-00806-f002){ref-type="fig"}). In silico predictions of the functional effect yielded conflicting results. PolyPhen-2 predicted the variant as benign with a score of 0.147 \[[@B37-genes-10-00806]\]. SIFT predicted that the variant affected protein function, with a score of 0.03 \[[@B38-genes-10-00806]\]. The SIFT prediction had low confidence due to the limited diversity of the available related sequences.

We confirmed the presence of the *TAC3* variant by Sanger sequencing and genotyped 171 control cats ([Figure 3](#genes-10-00806-f003){ref-type="fig"}). The case was homozygous for the mutant allele. Two domestic shorthair cats without reports of testicular hypoplasia or persistent primary dentition carried the alternative allele in a heterozygous state ([Table 3](#genes-10-00806-t003){ref-type="table"}; [Table S1](#app1-genes-10-00806){ref-type="app"}).

4. Discussion {#sec4-genes-10-00806}
=============

In this study, we identified a *TAC3*:c.220G\>A (p.Val74Met) missense variant in a domestic shorthair cat with absent puberty characteristics, such as normal testicle growth and change in primary dentition. The phenotype closely resembled HH, which belongs to the larger group of disorders of sexual development (DSD). The predicted amino acid substitution affects a moderately conserved region of the TAC3 precursor protein, which is 11 residues away from the mature neurokinin B sequence. The affected cat was homozygous for the mutant allele, which was found to be rare in the normal cat population. It should also be noted that the variant is close to the exon/intron boundary and might have an effect on splicing. Due to a lack of suitable RNA samples, we could not experimentally assess the *TAC3* mRNA splicing pattern in the affected cat.

Cases of human HH have been reported to be caused by variants in either the *TACR3* gene encoding the neurokinin B receptor or the *TAC3* gene itself \[[@B32-genes-10-00806],[@B39-genes-10-00806],[@B40-genes-10-00806],[@B41-genes-10-00806],[@B42-genes-10-00806],[@B43-genes-10-00806]\]. The phenotype of these patients is termed normosmic congenital hypogonadotropic hypogonadism (ncHH; OMIM \#614839). ncHH is clinically characterized by a failure to enter puberty. Female patients have amenorrhea, absent breast development, and hypoplastic ovaries and uteri. Male patients have small testicles and micropenis. Body hair growth in ncHH patients resembles a juvenile pre-puberty state. ncHH in humans can be successfully treated by pulsatile administration of GnRH \[[@B42-genes-10-00806]\] or steroid hormones \[[@B43-genes-10-00806]\]. The known human pathogenic *TAC3* variants consist of frameshift \[[@B43-genes-10-00806]\] and splice site \[[@B41-genes-10-00806],[@B42-genes-10-00806]\] variants and a single missense variant, p.M90T, which affects the C-terminal residue of the mature neurokinin B peptide \[[@B32-genes-10-00806]\]. Additional likely pathogenic missense variants affecting the mature neurokinin B sequence were deposited in the ClinVar database.

In felines, efforts are underway to develop a method to permanently sterilize cats by RNAi-mediated silencing of *KISS1* and *TAC3*. This method is predicted to lead to a reduction in the stray animal population and therefore decrease animal suffering and vectors for human disease \[[@B44-genes-10-00806]\].

5. Conclusions {#sec5-genes-10-00806}
==============

Our genetic data and existing knowledge regarding the physiological function of *TAC3* suggest that the *TAC3*:c.220G\>A (p.Val74Met) missense variant may be considered a candidate causative variant for the observed HH phenotype in the studied cat. Given that this is a single case investigation and that we have no functional confirmation of neurokinin B deficiency, this result must be considered preliminary and should be interpreted with caution.

The authors are grateful to the cat owner who donated samples and participated in the study. We thank Eva Andrist, Nathalie Besuchet Schmutz, Sabrina Schenk, and Daniela Steiner for their expert technical assistance, the Next Generation Sequencing Platform of the University of Bern for performing the high-throughput sequencing experiments, and the Interfaculty Bioinformatics Unit of the University of Bern for providing high performance computing infrastructure.

The following are available online at <https://www.mdpi.com/2073-4425/10/10/806/s1>, Table S1: TAC3:c.220G\>A genotypes of 172 cats from 13 different cat breeds; Table S2: Accession numbers of 39 cat genome sequences.
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![Clinical phenotype characterized by persistent primary dentition and an "unkempt" coat appearance.](genes-10-00806-g001){#genes-10-00806-f001}

![Multi-species protein alignment of the TAC3 precursor protein in the region of the missense variant. The valine at position 74 of the feline TAC3 protein is conserved in most mammals, except primates. The 10 amino acid sequence of the mature neurokinin B signaling peptide is indicated in red. Amino acid sequences were derived from XP_003988973.1 (cat); NP_037383.1 (human); XP_005625588.1 (dog); NP_851360.1 (cattle); NP_033338.2 (mouse); NP_062035.1 (rat).](genes-10-00806-g002){#genes-10-00806-f002}

![Details of the *TAC3*:c.220G\>A variant. Representative electropherograms of three cats with different genotypes are shown. Exonic bases are shown in capital letters and intronic bases in lowercase letters.](genes-10-00806-g003){#genes-10-00806-f003}
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###### 

Overview on genetic causes of human HH.

  Gene         Phenotype                                                  Inheritance   Ref.
  ------------ ---------------------------------------------------------- ------------- ---------------------------
  *CHD7*       Hypogonadotropic hypogonadism 5 with or without anosmia    AD            \[[@B5-genes-10-00806]\]
  *DAX1*       Adrenal hypoplasia, congenital                             XLR           \[[@B6-genes-10-00806]\]
  *DUSP6*      Hypogonadotropic hypogonadism 19 with or without anosmia   AD            \[[@B7-genes-10-00806]\]
  *FEZF1*      Hypogonadotropic hypogonadism 22 with or without anosmia   AR            \[[@B8-genes-10-00806]\]
  *FGF8*       Hypogonadotropic hypogonadism 6 with or without anosmia    AD            \[[@B9-genes-10-00806]\]
  *FGF17*      Hypogonadotropic hypogonadism 20 with or without anosmia   AD            \[[@B7-genes-10-00806]\]
  *FGFR1*      Hypogonadotropic hypogonadism 2 with or without anosmia    AD            \[[@B10-genes-10-00806]\]
  *FLRT3*      Hypogonadotropic hypogonadism 21 with anosmia              AD            \[[@B7-genes-10-00806]\]
  *FSHB*       Hypogonadotropic hypogonadism 24 without anosmia           AR            \[[@B11-genes-10-00806]\]
  *GNRH1*      Hypogonadotropic hypogonadism 12 with or without anosmia   AR            \[[@B12-genes-10-00806]\]
  *GNRHR*      Hypogonadotropic hypogonadism 7 without anosmia            AR            \[[@B13-genes-10-00806]\]
  *HESX-1*     Growth hormone deficiency with pituitary anomalies         AR, AD        \[[@B14-genes-10-00806]\]
  *HS6ST1*     Hypogonadotropic hypogonadism 15 with or without anosmia   AD            \[[@B7-genes-10-00806]\]
  *IL17RD*     Hypogonadotropic hypogonadism 18 with or without anosmia   AR, AD        \[[@B7-genes-10-00806]\]
  *KAL1*       Hypogonadotropic hypogonadism 1 with or without anosmia    XLR           \[[@B15-genes-10-00806]\]
  *KISS1*      Hypogonadotropic hypogonadism 13 with or without anosmia   AR            \[[@B16-genes-10-00806]\]
  *KISS1R*     Hypogonadotropic hypogonadism 8 with or without anosmia    AR            \[[@B17-genes-10-00806]\]
  *LEP*        Obesity, morbid, due to leptin deficiency                  AR            \[[@B18-genes-10-00806]\]
  *LEPR*       Obesity, morbid, due to leptin deficiency                  AR            \[[@B18-genes-10-00806]\]
  *LHB*        Hypogonadotropic hypogonadism 23 with or without anosmia   AR            \[[@B19-genes-10-00806]\]
  *LHX3*       Pituitary hormone deficiency, combined, 3                  AR            \[[@B20-genes-10-00806]\]
  *NELF*       Hypogonadotropic hypogonadism 9 with or without anosmia    AD            \[[@B21-genes-10-00806]\]
  *OTUD4*      Gordon Holmes syndrome                                     AR            \[[@B22-genes-10-00806]\]
  *PNPLA6*     Boucher--Neuhauser Syndrome                                AR            \[[@B23-genes-10-00806]\]
  *POLR3B*     hypogonadotropic hypogonadism                              AR            \[[@B24-genes-10-00806]\]
  *PROK2*      Hypogonadotropic hypogonadism 4 with or without anosmia    AD            \[[@B25-genes-10-00806]\]
  *PROKR2*     Hypogonadotropic hypogonadism 3 with or without anosmia    AD            \[[@B25-genes-10-00806]\]
  *PROP-1*     Pituitary hormone deficiency, combined, 2                  AR            \[[@B26-genes-10-00806]\]
  *RAB18*      Warburg micro syndrome 3                                   AR            \[[@B27-genes-10-00806]\]
  *RAB3GAP1*   Warburg micro syndrome 1                                   AR            \[[@B27-genes-10-00806]\]
  *RAB3GAP2*   Warburg micro syndrome 2                                   AR            \[[@B27-genes-10-00806]\]
  *RNF216*     Cerebellar ataxia and hypogonadotropic hypogonadism        AR            \[[@B28-genes-10-00806]\]
  *SEMA3A*     Hypogonadotropic hypogonadism 16 with or without anosmia   AD            \[[@B29-genes-10-00806]\]
  *SOX2*       Abnormalities of the central nervous system                AD            \[[@B30-genes-10-00806]\]
  *SPRY4*      Hypogonadotropic hypogonadism 17 with or without anosmia   AD            \[[@B7-genes-10-00806]\]
  *STUB1*      Spinocerebellar ataxia, autosomal recessive 16             AR            \[[@B31-genes-10-00806]\]
  *TAC3*       Hypogonadotropic hypogonadism 10 with or without anosmia   AR            \[[@B32-genes-10-00806]\]
  *TACR3*      Hypogonadotropic hypogonadism 11 with or without anosmia   AR            \[[@B32-genes-10-00806]\]
  *TBC1D20*    Warburg micro syndrome 4                                   AR            \[[@B33-genes-10-00806]\]
  *WDR11*      Hypogonadotropic hypogonadism 14 with or without anosmia   AD            \[[@B34-genes-10-00806]\]

genes-10-00806-t002_Table 2

###### 

Results of variant filtering.

  Filtering Step                              Homozygous Variants   Heterozygous Variant
  ------------------------------------------- --------------------- ----------------------
  Private variants                            25,355                209,967
  Protein-changing private variants           111                   756
  Private variants in known candidate genes   1                     0

genes-10-00806-t003_Table 3

###### 

Genotype phenotype association of the *TAC3*:c.220G\>A variant.

  Cats                       G/G   G/A   A/A
  -------------------------- ----- ----- -----
  Cases (*n* = 1)            0     0     1
  Control cats (*n* = 171)   169   2     0
